The estimated Net Worth of Steffen Thomas is at least $120 Tisíc dollars as of 15 May 2024. Steffen Thomas owns over 5,000 units of Anavex Life Sciences stock worth over $25,650 and over the last 8 years he sold AVXL stock worth over $0. In addition, he makes $93,871 as Independent Director at Anavex Life Sciences.
Steffen has made over 1 trades of the Anavex Life Sciences stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of AVXL stock worth $22,600 on 15 May 2024.
The largest trade he's ever made was buying 5,000 units of Anavex Life Sciences stock on 15 May 2024 worth over $22,600. On average, Steffen trades about 556 units every 0 days since 2016. As of 15 May 2024 he still owns at least 5,000 units of Anavex Life Sciences stock.
You can see the complete history of Steffen Thomas stock trades at the bottom of the page.
Dr. Steffen Thomas Ph.D. serves as Independent Director of the Company. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.
As the Independent Director of Anavex Life Sciences, the total compensation of Steffen Thomas at Anavex Life Sciences is $93,871. There are 5 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.
Steffen Thomas is 54, he's been the Independent Director of Anavex Life Sciences since 2015. There are 2 older and 5 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.
Steffen's mailing address filed with the SEC is 630 5TH AVENUE, 20TH FLOOR, , NEW YORK, NY, 10111.
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling a Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Anavex Life Sciences executives and other stock owners filed with the SEC include: